Glycogenolytic effect of vasoactive intestinal peptide in the rat in vivo.
The effects of VIP (300 pmol/kg), injected via the portal vein, on the glycogen content of the liver and on glycemia, were studied in the rat in vivo. VIP enhanced glycogenolysis and caused hyperglycemia in a time-dependent manner.
Sánchez
V
V
Department of Medical Biochemistry and Molecular Biology, Medical School, University of Sevilla, Spain.
Goberna
R
R
Calvo
J R
JR
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D005934:Glucagon / Q000097:blood; D006003:Glycogen / Q000378:metabolism*; D007275:Injections, Intravenous; D007328:Insulin / Q000097:blood; D007700:Kinetics; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D011169:Portal Vein; D051381:Rats; D011919:Rats, Inbred Strains; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D014660:Vasoactive Intestinal Peptide; D006003:Glycogen; D005934:Glucagon